Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee

Christoph Seger; Maria Shipkova; Uwe Christians; Elaine M. Billaud; Ping Wang; David W. Holt; Merce Brunet; Pawe K. Kunicki; Thomasz Pawinski; Loralie J. Langman; Pierre Marquet; Michael Oellerich; Eberhard Wieland; Pierre Wallemacq

doi:10.1097/FTD.0000000000000269

Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee

Christoph Seger, Maria Shipkova, Uwe Christians, Elaine M. Billaud, Ping Wang, David W. Holt, Merce Brunet, Pawe K. Kunicki, Thomasz Pawinski, Loralie J. Langman, Pierre Marquet, Michael Oellerich, Eberhard Wieland, Pierre Wallemacq

Research output: Contribution to journal › Review article › peer-review

91 Scopus citations

Abstract

Monitoring immunosuppressive drugs (ISDs) in blood or plasma is still a key therapeutic drug monitoring (TDM) application in clinical settings. Narrow target ranges and severe side effects at drug underexposure or overexposure make accurate and precise measurements a must. This overview prepared by the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is intended to serve as a summary and guidance document describing the current state-of-the-art in the TDM of ISDs.

Original language	English (US)
Pages (from-to)	170-189
Number of pages	20
Journal	Therapeutic Drug Monitoring
Volume	38
Issue number	2
DOIs	https://doi.org/10.1097/FTD.0000000000000269
State	Published - 2016

Keywords

Cyclosporine
Design
Everolimus
Immunoassay
Immunosuppressant drugs
LC-MS/MS
Mycophenolic acid
Sirolimus
TDM
Tacrolimus
Validation
Verification

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1097/FTD.0000000000000269

Fingerprint

Dive into the research topics of 'Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee'. Together they form a unique fingerprint.

Cite this

Seger, C., Shipkova, M., Christians, U., Billaud, E. M., Wang, P., Holt, D. W., Brunet, M., Kunicki, P. K., Pawinski, T., Langman, L. J., Marquet, P., Oellerich, M., Wieland, E., & Wallemacq, P. (2016). Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee. Therapeutic Drug Monitoring, 38(2), 170-189. https://doi.org/10.1097/FTD.0000000000000269

Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee. / Seger, Christoph; Shipkova, Maria; Christians, Uwe et al.
In: Therapeutic Drug Monitoring, Vol. 38, No. 2, 2016, p. 170-189.

Research output: Contribution to journal › Review article › peer-review

Seger, C, Shipkova, M, Christians, U, Billaud, EM, Wang, P, Holt, DW, Brunet, M, Kunicki, PK, Pawinski, T, Langman, LJ, Marquet, P, Oellerich, M, Wieland, E & Wallemacq, P 2016, 'Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee', Therapeutic Drug Monitoring, vol. 38, no. 2, pp. 170-189. https://doi.org/10.1097/FTD.0000000000000269

Seger C, Shipkova M, Christians U, Billaud EM, Wang P, Holt DW et al. Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee. Therapeutic Drug Monitoring. 2016;38(2):170-189. doi: 10.1097/FTD.0000000000000269

Seger, Christoph ; Shipkova, Maria ; Christians, Uwe et al. / Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice : Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee. In: Therapeutic Drug Monitoring. 2016 ; Vol. 38, No. 2. pp. 170-189.

@article{b7f8eb7229d844e9972b219373e9066f,

title = "Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee",

abstract = "Monitoring immunosuppressive drugs (ISDs) in blood or plasma is still a key therapeutic drug monitoring (TDM) application in clinical settings. Narrow target ranges and severe side effects at drug underexposure or overexposure make accurate and precise measurements a must. This overview prepared by the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is intended to serve as a summary and guidance document describing the current state-of-the-art in the TDM of ISDs.",

keywords = "Cyclosporine, Design, Everolimus, Immunoassay, Immunosuppressant drugs, LC-MS/MS, Mycophenolic acid, Sirolimus, TDM, Tacrolimus, Validation, Verification",

author = "Christoph Seger and Maria Shipkova and Uwe Christians and Billaud, {Elaine M.} and Ping Wang and Holt, {David W.} and Merce Brunet and Kunicki, {Pawe K.} and Thomasz Pawinski and Langman, {Loralie J.} and Pierre Marquet and Michael Oellerich and Eberhard Wieland and Pierre Wallemacq",

year = "2016",

doi = "10.1097/FTD.0000000000000269",

language = "English (US)",

volume = "38",

pages = "170--189",

journal = "Therapeutic Drug Monitoring",

issn = "0163-4356",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice

T2 - Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee

AU - Seger, Christoph

AU - Shipkova, Maria

AU - Christians, Uwe

AU - Billaud, Elaine M.

AU - Wang, Ping

AU - Holt, David W.

AU - Brunet, Merce

AU - Kunicki, Pawe K.

AU - Pawinski, Thomasz

AU - Langman, Loralie J.

AU - Marquet, Pierre

AU - Oellerich, Michael

AU - Wieland, Eberhard

AU - Wallemacq, Pierre

PY - 2016

Y1 - 2016

N2 - Monitoring immunosuppressive drugs (ISDs) in blood or plasma is still a key therapeutic drug monitoring (TDM) application in clinical settings. Narrow target ranges and severe side effects at drug underexposure or overexposure make accurate and precise measurements a must. This overview prepared by the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is intended to serve as a summary and guidance document describing the current state-of-the-art in the TDM of ISDs.

AB - Monitoring immunosuppressive drugs (ISDs) in blood or plasma is still a key therapeutic drug monitoring (TDM) application in clinical settings. Narrow target ranges and severe side effects at drug underexposure or overexposure make accurate and precise measurements a must. This overview prepared by the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is intended to serve as a summary and guidance document describing the current state-of-the-art in the TDM of ISDs.

KW - Cyclosporine

KW - Design

KW - Everolimus

KW - Immunoassay

KW - Immunosuppressant drugs

KW - LC-MS/MS

KW - Mycophenolic acid

KW - Sirolimus

KW - TDM

KW - Tacrolimus

KW - Validation

KW - Verification

UR - http://www.scopus.com/inward/record.url?scp=84962171239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962171239&partnerID=8YFLogxK

U2 - 10.1097/FTD.0000000000000269

DO - 10.1097/FTD.0000000000000269

M3 - Review article

AN - SCOPUS:84962171239

SN - 0163-4356

VL - 38

SP - 170

EP - 189

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

IS - 2

ER -

Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this